Pulmonary Pharmacology & Therapeutics

Papers
(The median citation count of Pulmonary Pharmacology & Therapeutics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Applicability of mouse models for induction of severe acute lung injury56
The promoting role of Cx43 on the proliferation and migration of arterial smooth muscle cells for angiotensin II-dependent hypertension53
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis40
Editorial Board36
Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia32
Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers31
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis31
Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis27
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis25
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)23
Editorial Board22
Editorial Board18
Editorial Board17
Enlightening clinical and therapeutic heterogeneity in thoracic actinomycosis: A review in bronchiectasis and non-bronchiectasis patients17
Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry17
Effect of centrally and peripherally acting GABAB agonism on the healthy human cough reflex16
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies15
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers15
Risk factors associated with increased discontinuation rate of trimethoprim–sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study15
TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: First experience15
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study14
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study13
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis12
CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis12
Development of an inhaled anti-TSLP therapy for asthma12
Efficacy and safety of inhaled nebulized sodium nitrite in asthmatic patients12
Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels11
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation11
Mechanistic insights into the amelioration effects of lipopolysaccharide-induced acute lung injury by baicalein: An integrated systems pharmacology study and experimental validation11
Editorial Board11
Chrysin prevents lipopolysaccharide-induced acute lung injury in mice by suppressing the IRE1α/TXNIP/NLRP3 pathway10
HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB310
Interaction between fluticasone furoate and umeclidinium in passively sensitized isolated human airways9
FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer9
Ensifentrine approval: A milestone in the treatment of COPD9
Serum dipeptidyl peptidase-4 and eosinophil cationic protein levels in patients of bronchial asthma8
Corrigendum to “Presence and function of β-adrenergic receptors in primary equine bronchial epithelia cells” [Pulm Pharmacol Ther. (2020 Apr) 61 101897] DOI: 10.1016/j.pupt.2020.1018978
IRE1α/XBP-1 promotes β-catenin signaling activation of airway epithelium in lipopolysaccharide-induced acute lung injury8
Prevalence and clinical significance of pre- and post-bronchodilator airflow obstruction in COPD patients7
The inflammatory regulation of TRPA1 expression in human A549 lung epithelial cells7
Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study7
Impacts of deficiency in vitamin D derivatives on disease severity in adult bronchial asthma patients7
Editorial Board6
A retro-inverso modified peptide alleviated ovalbumin-induced asthma model by affecting glycerophospholipid and purine metabolism of immune cells6
Editorial Board6
Commercial α1-antitrypsin preparations markedly differ in their potential to inhibit the ATP-induced release of monocytic interleukin-1β6
Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia6
The involvement of Sting in exacerbating acute lung injury in sepsis via the PARP-1/NLRP3 signaling pathway6
Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-196
Real world outcomes of CFTR modulator therapy in Australian adults and children6
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens6
Editorial Board5
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers5
Tanshinone IIA alleviates bleomycin-induced pulmonary fibrosis by inhibiting Zbtb165
SIRT3 alleviates sepsis-induced acute lung injury by inhibiting pyroptosis via regulating the deacetylation of FoxO3a5
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function5
Editorial Board5
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study5
Editorial Board5
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients5
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d5
The roles of immune system and autoimmunity in pulmonary arterial hypertension: A review4
Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study4
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics4
Effect of functional principle, delivery technique, and connection used on aerosol delivery from different nebulizers: An in-vitro study4
Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients 4
Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects4
Which LABA/LAMA should be chosen in COPD patients in real life?4
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome4
Dihydroquercetin (DHQ) ameliorates LPS-induced acute lung injury by regulating macrophage M2 polarization through IRF4/miR-132-3p/FBXW7 axis4
Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted4
WITHDRAWN: Oncogenic lncRNA MALAT-1 recruits E2F1 to upregulate RAD51 expression and thus promotes cell autophagy and tumor growth in non-small cell lung cancer4
Allopurinol treatment reduced vascular remodeling and improved vascular functions in monocrotaline-induced pulmonary hypertensive rats4
Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway4
Leukotriene inhibition and the risk of lung cancer among U.S. veterans with asthma4
NEK-mediated barrier regulation4
Pulmonary drug delivery for acute respiratory distress syndrome4
Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma4
IL-10RA promotes lung cancer cell proliferation by increasing fatty acid oxidation via STAT3 signaling pathway4
Editorial Board3
Chest CT assess the impact of omalizumab treatment on airway remodeling in refractory asthma3
Assessing the relationship between cardiovascular and small airway disease and acute events in COPD: The ARCADIA study protocol3
Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling3
May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?3
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians3
Assessment of extrafine beclomethasone/formoterol for the treatment of chronic obstructive pulmonary disease: A non-interventional study in a Bulgarian population3
Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study3
Inhibition of poly (ADP-ribose) Polymerase-1 (PARP-1) improves endothelial function in pulmonary hypertension3
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets3
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arter3
Editorial Board3
Corrigendum to “Clinical efficacy of inhaled corticosteroids in equine asthma: A meta-analysis and number needed to treat” [Pulm. Pharmacol. Therapeut. (88), March 2025, 102342]3
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease3
Editorial Board3
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality3
Editorial Board3
Protective effects of adipose-derived biogenic nanoparticles on the pulmonary microvascular endothelial barrier in mice with ventilator-induced lung injury via the TRPV4/ROCK1 signalling pathway2
Differential effects of dexamethasone and roflumilast on asthma in mice with or without short cigarette smoke exposure2
Aerosolized Beractant in neonatal respiratory distress syndrome: A randomized fixed-dose parallel-arm phase II trial2
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats2
Corrigendum to “Myricetin inhibits TNF-α-induced inflammation in A549 cells via the SIRT1/NF-κB pathway” [Pulm. Pharmacol. Therapeut. 65 (2020) 102000]2
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential2
Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma2
Editorial Board2
“The possible implication of endothelin in the pathology of COVID-19-induced pulmonary hypertension”2
Pyrroloquinoline quinone (PQQ) improves pulmonary hypertension by regulating mitochondrial and metabolic functions2
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients2
Corrigendum to “Bleomycin induced lung fibrosis increases work of breathing in the mouse” [Pulm. Pharmacol.Therapeut. 25 (2012) 281-285]2
Medication use in people with cystic fibrosis before and after modulator therapy2
Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan2
Statins’ still controversial role in pulmonary fibrosis: What does the evidence show?2
Hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer2
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea2
Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants2
Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression2
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma2
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study2
0.048577070236206